Effect of Immunosuppression in IgA Nephropathy

Launched by YONSEI UNIVERSITY · Mar 12, 2018

Keywords

ClinConnect Summary

The investigators will conduct a multicenter prospective randomized controlled open-label trial; a step-wise therapeutic approach in IgAN patients with persistent proteinuria who have preserved eGFR of ≥ 30 ml/min/1.73 m2. During 3-6 months before the enrollment, all patients will receive maximal supportive care including the use of RAS blockers, blood pressure control with a target of \<130/80 mmHg, and protein restriction diet. If proteinuria does not decrease \< 1.0 g/g creatinine, patients will be randomly assigned to continue supportive care, or to receive corticosteroids. At 3 months ...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Biopsy-proven IgA nephropathy within 5 years of enrollment
• • Persistent proteinuria of UPCR ≥ 1.0 g/g creatinine during 12-week supportive care including RAS blockers
• • baseline eGFR ≥ 30 ml/min/1.73 m2 assessed by CKD-EPI equation
• Exclusion Criteria:
• • Nephrotic syndrome, atypical IgA nephropathy
• • Crescents ≥ 25%
• • Overt pulmonary tuberculosis
• • Malignancy within 5 years of enrollment
• • Pregnancy or breast feeding
• • Active hepatitis, chronic hepatitis, liver cirrhosis, HIV
• • Kidney transplant
• • Current use of immunosuppressive treatment or prior use of immunosuppressive drugs within 1 year of enrollment
• • Uncontrolled hypertension (\> 160/100 mmHg)
• • Aged \< 19 years
• • Secondary IgA nephropathy such as lupus nephritis, chronic liver disease, or Henoch-Schlein purpura
• • Involvement of other clinical trials within 3 months of enrollment